MXPA03001434A - Metodos y composiciones para el tratamiento de la enfermedad relacionada con la inmunoglobulina e, utilizando inhibidores del factor neutrofico 1 novedoso. - Google Patents

Metodos y composiciones para el tratamiento de la enfermedad relacionada con la inmunoglobulina e, utilizando inhibidores del factor neutrofico 1 novedoso.

Info

Publication number
MXPA03001434A
MXPA03001434A MXPA03001434A MXPA03001434A MXPA03001434A MX PA03001434 A MXPA03001434 A MX PA03001434A MX PA03001434 A MXPA03001434 A MX PA03001434A MX PA03001434 A MXPA03001434 A MX PA03001434A MX PA03001434 A MXPA03001434 A MX PA03001434A
Authority
MX
Mexico
Prior art keywords
nnt
ige
fragment
polypeptide
inhibitor
Prior art date
Application number
MXPA03001434A
Other languages
English (en)
Spanish (es)
Inventor
Giorgio Senaldi
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MXPA03001434A publication Critical patent/MXPA03001434A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA03001434A 2000-08-18 2001-08-17 Metodos y composiciones para el tratamiento de la enfermedad relacionada con la inmunoglobulina e, utilizando inhibidores del factor neutrofico 1 novedoso. MXPA03001434A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22643600P 2000-08-18 2000-08-18
US09/931,704 US6849260B2 (en) 2000-08-18 2001-08-16 Methods and compositions for treating IgE-related disease using NNT-1 inhibitors
PCT/US2001/025906 WO2002015977A2 (en) 2000-08-18 2001-08-17 Methods and compositions for treating ige-related disease using nnt-1 inhibitors

Publications (1)

Publication Number Publication Date
MXPA03001434A true MXPA03001434A (es) 2004-12-13

Family

ID=26920541

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001434A MXPA03001434A (es) 2000-08-18 2001-08-17 Metodos y composiciones para el tratamiento de la enfermedad relacionada con la inmunoglobulina e, utilizando inhibidores del factor neutrofico 1 novedoso.

Country Status (7)

Country Link
US (1) US6849260B2 (enExample)
EP (1) EP1309374A2 (enExample)
JP (1) JP2004513081A (enExample)
AU (2) AU2001283451A1 (enExample)
CA (1) CA2419274A1 (enExample)
MX (1) MXPA03001434A (enExample)
WO (1) WO2002015977A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076288A2 (en) * 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100365064B1 (ko) 1994-10-17 2003-04-11 훽스트파마슈티칼스앤드케미칼스가부시키가이샤 I형알레르기성질환의예방및치료제
EP0839155B1 (en) 1995-07-17 2004-10-13 Medivir UK Ltd CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES
US5741772A (en) 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
IL154543A0 (en) 1997-02-03 2003-09-17 Amgen Inc The neurotrophic factor nnt-1
CA2295326A1 (en) 1997-06-30 1999-01-07 Human Genome Sciences, Inc. Cardiotrophin-like cytokine
GB9913327D0 (en) 1999-06-08 1999-08-11 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
AU2001283451A1 (en) 2002-03-04
JP2004513081A (ja) 2004-04-30
EP1309374A2 (en) 2003-05-14
WO2002015977A2 (en) 2002-02-28
CA2419274A1 (en) 2002-02-28
WO2002015977A3 (en) 2002-11-28
AU2005232321A1 (en) 2005-12-01
US20020041873A1 (en) 2002-04-11
US6849260B2 (en) 2005-02-01

Similar Documents

Publication Publication Date Title
JP4638876B2 (ja) Ｇｉｔｒリガンド及びｇｉｔｒリガンド関連分子及び抗体及びその使用
ES2257739T3 (es) Antigenos ctla-8 de primate purificados y reactivos relacionados.
US20090280082A1 (en) Methods for treating autoimmune disorders
JP2011132260A (ja) 転移を阻害する方法
JP2007523169A (ja) 免疫疾患を治療するための、ｐ２８、ＥＢＩ３およびＷＳＸ／ＴＣＣＲのアゴニストおよびアンタゴニスト
JP2000514295A (ja) 哺乳動物のケモカイン試薬
RU2530561C2 (ru) Способы лечения склеродермии
DE69630682T2 (de) Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes
JP4864278B2 (ja) 脱髄疾患を処置する方法
AU2001288286A1 (en) Methods for treating demyelinating diseases
US6849260B2 (en) Methods and compositions for treating IgE-related disease using NNT-1 inhibitors
KR20070007291A (ko) 면역 반응을 유도하거나 조절하는 방법
US20080226631A1 (en) Methods of modulating cytokine activity; related reagents
JP2002514067A (ja) 神経栄養因子ｎｎｔ−１
US6824781B2 (en) Method of impairing movement of a CLA + memeory T-cell within or to the skin of a mammal by administering a CTACK antagonist
US20040219149A1 (en) Methods for the modulation of il-13
CN114901313A (zh) 急性期的视神经脊髓炎的预防或治疗剂
US20040096446A1 (en) Methods for treating demyelinating diseases
Doll Development of therapeutic proteins for the treatment of rheumatoid arthritis and chronic cardiac rejection
AU2007201935A1 (en) Methods for treating demyelinating disease

Legal Events

Date Code Title Description
FA Abandonment or withdrawal